Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
Trial details
- Registry ID
- NCT06126380
- Phase
- Phase 2
The FDA approved Tacrolimus on 8 Apr 1994.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsNCT06126380 | Eledon Pharmaceuticals | Phase 2 | Enrolling by invitation | 2029-12Estimated |
| Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationNCT05983770 | Eledon Pharmaceuticals | Phase 2 | Completed | 2025-09-11Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1994-04-08Day | Tacrolimus | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA050708", "applicant_as_listed_by_fda": "ASTELLAS", "brand_names": ["PROGRAF"], "active_ingredients": ["TACROLIMUS"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19940408", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |